Stock Ratings / Health Care / PULM / forecast

PCSA (48) CANF (31) ADXN (57) XBIO (47) ⌘ Pro Terminal →

Pulmatrix Inc. (PULM) 12-Month Stock Forecast & Price Target Cone

$1.42 -5.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Pulmatrix Inc. (PULM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $5.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PULM)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PULM Position Size: $10,000

Shares at $1.42: 7042.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.00

$7,042

$-2,958 (-29.6%)

12M Consensus BaseTarget $1.28

$9,014

$-986 (-9.9%)

12M Bull Case BreakoutTarget $5.24

$36,901

+$26,901 (+269.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$5	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PULM)

✓Walkthrough of PULM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PULM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.70%📐 HORIZONTAL RANGE

2026-10-30O $1.41H $1.45L $1.35C $1.42VOL 9.6K

RES: $1.77SUP: $1.15SMA50: $1.49SMA200: $1.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PULM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PULM Butterfly Map → + Track PULM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PULM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PULM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PULM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PULM)

Health Care Rank #802 of 1016 ⚔️ PCSA vs PULM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PULM vs. PCSA, CANF, ADXN, XBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pulmatrix Inc. (PULM) ranks #802 by composite RQD confidence (36/100, grade D-) and #944 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, PULM leads on earnings valuation at N/A trailing P/E, while XBIO leads on capital efficiency and profitability with -30.3% ROIC and — gross margin. ADXN currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with PULM at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PULM ACTIVE Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	Benchmark Subject
PCSA Processa Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+2.16%	$5.3M	/pcsa-vs-pulm →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	31/100	—	—	-35.0%	+0.61%	$5.0M	/canf-vs-pulm →
ADXN Addex Therapeutics Ltd	D+	57/100	—	—	—	-1.01%	$5.0M	/adxn-vs-pulm →
XBIO Xenetic Biosciences Inc.	D	47/100	—	—	-30.3%	+0.95%	$5.0M	/xbio-vs-pulm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001574235

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulmatrix Inc. (PULM) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $7.8M , and -100.0% cumulative change since FY2023) , GAAP net income of -$5.2M, operating cash flow of -$5.4M, and free cash flow of -$5.4M (+51.1% YoY). On the balance sheet, PULM closed FY2025 with $4.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$5.2M	-$5.4M	-$5.4M	$4.1M	—
FY2024 (FY)	2024-12-31	$7.8M	-$9.6M	-$10.7M	-$11.1M	$9.9M	—
FY2023 (FY)	2023-12-31	$7.3M	-$14.1M	-$16.0M	-$16.0M	—	—

3. PULM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PULM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pulmatrix Inc. (NASDAQ: PULM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.42 (-5.67% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PULM ranks #802 in composite RQD confidence.

How does PULM compare to PCSA and CANF in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PULM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PCSA (Processa Pharmaceuticals Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and CANF (Can-Fite Biopharma Ltd each representing two (2)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.0M). Among the 5-stock peer group, PULM leads on earnings multiple (N/A) while XBIO leads on capital efficiency (-30.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PULM?

Per PULM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574235), Pulmatrix Inc. generated $0 in revenue (-100.0% YoY), -$5.2M in net income, and -$5.4M in free cash flow against $4.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PULM trading relative to its 50-day, 200-day, and 52-week technical levels?

PULM last traded at $1.42 (-5.67% on volume of 5,908 shares), positioning the stock -4.70% below its 50-day simple moving average ($1.49) and -16.96% below its 200-day simple moving average ($1.71). Across its 52-week range of $1.16 to $4.99, PULM sits at the 6.8% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.24 to $1.60).

PULM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PULM's 12-month stock price target?

Pulmatrix Inc. (PULM) carries a 12-month consensus base price target of $1.28 (-9.9% from $1.42), with a bull-case target of $5.24 and a bear-case floor of $1.